Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
BAY94-9392 · 1 trial · 2 indications
| Arm | Type | Description |
|---|---|---|
| Arm 1 | EXPERIMENTAL | Cancer patients, single intravenous bolus injection of 300 MBq BAY94-9392 on day one of the treatment period, PET/CT |
| Arm 2 | EXPERIMENTAL | Healthy volunteers, single intravenous bolus injection of 300 MBq BAY94-9392 on day one of the treatment period, whole body PET/CT for determination of effective dose, kinetics of BAY94-9392 in blood |
| Name | Type | Description |
|---|---|---|
| BAY94-9392 | DRUG | - |
Inclusion criteria: In Germany Healthy volunteers * Males/females ≥ 50 and ≤ 65 years Patients * Males/females ≥ 35 and ≤ 75 years * histologically confirmed diagnosis of non small cell lung cancer or adenocarcinoma of the breast with a positive FDG-PET or * patient with primary prostate cancer sc...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Hologic, Inc. | HOLX | 1 | N/A | Undisclosed |
| Intelligent Bio Solutions Inc. | INBS | 1 | - | Undisclosed |
| HeartFlow, Inc. | HTFL | 1 | N/A | Rosuvastatin |
| GE Healthcare Technologies Inc. | GEHC | 2 | N/A | Undisclosed |
BAY94-9392 is an investigational small molecule being developed for diagnostic imaging in oncology. It is being studied as a positron emission tomography (PET) imaging agent to visualize cancer and inflammation in patients. The drug is in Phase 1 clinical development and is not yet approved by regulatory authorities.
BAY94-9392 is a small molecule PET imaging agent designed to detect cancer and inflammation. While its specific molecular target is not disclosed, it is being evaluated for its ability to image neoplasms and inflammatory conditions. The drug is in Phase 1 trials to assess its safety, metabolism, and imaging properties.
BAY94-9392 is being developed by Lantheus Holdings, Inc. (NASDAQ: LNTH), a company focused on diagnostic imaging agents. The drug is currently in Phase 1 clinical development for oncology imaging applications.
BAY94-9392 is in Phase 1 clinical development. A single Phase 1 trial has been completed, which evaluated the drug's radiation dosimetry, metabolism, pharmacokinetics, safety, tolerability, and PET imaging capabilities in healthy volunteers and patients with cancer or inflammation. The drug remains investigational.
BAY94-9392 has one completed clinical trial, NCT01103310, which enrolled 46 participants. The study assessed radiation dosimetry, metabolism, pharmacokinetics, safety, tolerability, and PET imaging in healthy volunteers and patients with cancer or inflammation. The trial was conducted in the United States, Germany, and South Korea.